News | Blood Testing | April 13, 2017

New Study Pursues Universal Sample Bank for Troponin Tests

Researchers hope to improve consistency among blood tests used to diagnose heart attacks

New Study Pursues Universal Sample Bank for Troponin Tests

April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC) Journal of Applied Laboratory Medicine describes the creation of a first-of-its-kind patient sample bank that could improve consistency among blood tests used to diagnose heart attacks and advance care for cardiac patients.

In the emergency room, a blood test for cardiac troponin — a protein released when cardiac cells are damaged — is used to identify chest pain patients who are having a heart attack so that they can be treated as quickly as possible. Specifically, a heart attack is diagnosed when a patient’s troponin concentrations exceed those found in the 99th percentile of a healthy reference population. However, the 99th percentile cutoff value varies for different troponin tests because each test manufacturer uses a different reference population. Therefore, there is a need to have samples available from one healthy reference population so that all manufacturers can use the same population to determine a universal 99th percentile cutoff for troponin. This will help to ensure that cardiac patients receive the same diagnosis and quality of care regardless of what hospital they go to and what troponin test is used.

This study examines the universal sample bank of ethnically and geographically diverse healthy subjects that AACC created to ensure that cardiac patients have consistent quality of diagnosis and care. Participants were recruited from among attendees of the 2015 AACC Annual Meeting & Clinical Lab Expo, the world’s largest conference for laboratory medicine, as well as at the University of Maryland. From those individuals who met initial eligibility criteria, 60 mL of blood was collected and tested for hemoglobin A1c, N-terminal pro–B-type natriuretic peptide and creatinine. These tests were used to exclude participants with uncontrolled diabetes, renal insufficiency, and heart disease, including most asymptomatic cardiac conditions.

In total, 808 individuals were included in the sample bank: 402 females and 406 males who are 60 percent Caucasian, 26 percent African or African American, 11 percent Asian or Pacific Islander, and 3 percent other. This sample bank and its associated data provides a unique opportunity for diagnostic manufacturers to generate a reliable 99th percentile value that applies to all troponin tests, which in turn could prevent delays in heart attack patients receiving critical treatment.

“The 99th percentiles can now be assessed by assay manufacturers and laboratories using the same patient population,” said senior paper author Robert Christenson, Ph.D., of the University of Maryland School of Medicine. “This enables establishing and applying clinical decision points in an effective and consistent manner. [Additionally,] this sample bank can and likely will be used for the determination of reference ranges for other clinical laboratory tests.”

For more information: www.aacc.org

Related Content

New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
Feature | Inventory Management| April 28, 2017 | Dave Fornell
Tracking cardiovascular device inventory in cath labs, electrophysiology (EP) labs and operating rooms (ORs) can be a
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock
Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
New Hampshire Hospital Expands Vascular Care with Toshiba Medical's Infinix-I Sky +
News | Angiography| April 27, 2017
Wentworth-Douglass Hospital in Dover, N.H., installed Toshiba Medical’s Infinix-i Sky + angiography system in its...
Mercator MedSystems Announces First Enrollment in TANGO Trial for Below-the-Knee Vascular Disease
News | Peripheral Arterial Disease (PAD)| April 27, 2017
Mercator MedSystems Inc. announced the first patient enrollment into the TANGO (Temsirolimus Adventitial Delivery to...
News | Venous Therapies| April 26, 2017
A new Varicose Vein Registry has begun producing useful outcomes information, as reported in the May edition of the...
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons| April 26, 2017
Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Balloon Catheter at...
AATS Consensus Statement Helps Manage Treatment of Coronary Anomalies
News | Cardiac Diagnostics| April 26, 2017
The issues surrounding congenital coronary anomalies and their effect on sudden death are complex. Researchers are...
Body Weight Fluctuations Linked to More Deaths in People with Coronary Artery Disease
News | Cardiac Diagnostics| April 25, 2017
Repeated cycles of weight loss and gain may be linked to higher risk for stroke, heart attack and death in people with...
Overlay Init